US EditionInnovent Presents Updated IBI363 Data in Colorectal Cancer at ASCO 2025
- Innovent Biologics announced on June 1, 2025, updated Phase 1 and 2 clinical data of IBI363 for colorectal cancer and melanoma at ASCO 2025 in San Francisco and Suzhou, China.
- The data follow prior immunotherapy treatments and focus on unresectable mucosal and acral melanoma, addressing cold tumors resistant to conventional therapies.
- Among 31 patients treated at 1 mg/kg biweekly, IBI363 showed a 23.3% confirmed objective response rate and a 76.7% disease control rate, with median progression-free survival of 5.7 months.
- The median overall survival reached 14.8 months with 61.5% 12-month survival, and treatment-related adverse events like arthralgia and rash were mostly Grade 1 or 2 and manageable.
- These results support ongoing pivotal trials comparing IBI363 to pembrolizumab in untreated mucosal and acral melanoma, suggesting potential for broader clinical use and improved patient outcomes.
65 Articles
65 Articles
Helena Independent Record
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…
Innovent presents updated IBI363 data in colorectal cancer at ASCO 2025
SAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)…
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma - PressReach
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ — Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the data from Phase 1 and Phase 2 clinical studies of IBI363, first-in-class PD-1/IL-2α-bias bispecific ant…
Coverage Details
Bias Distribution
- 78% of the sources are Center
To view factuality data please Upgrade to Premium
